This symposium is designed to review the importance of chronic kidney disease (CKD) risk reduction in patients with T2D, how to evaluate opportunities to screen for CKD risk in patients with T2D and target reductions in albuminuria, the manageability of hyperkalemia and uniqueness of novel therapy, and key takeaways and practice changes.

Our Agenda
7:00 PM – 8:00 PM CDT


Robert Toto, MD

Director, Clinical Nephrology
Director, Patient-Oriented Research in Nephrology
University of Texas Southwestern Medical Center
Dallas, TX

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, FL

Open Technology for Social Good
Scroll to Top